Meloxicam

2025年4月7日 ，Viatris（晖致公司）（“公司”）对外宣布，公司已达成一项全国性和解框架，以解决各州、地方政府和部落对公司及其某些子公司提起的阿片类药物相关索赔。尽管公司在美国阿片类药物市场的份额非常小，但公司仍同意此次和解，以为这些事项画上句号。此和解绝非对公司有任何不当行为或责任的承认。根据已达成的和解框架，根据和解的参与程度，公司将支付最高达3.35亿美元的和解金，这笔资金将在九年内以每年约2,750万至4,000万美元的分期付款形式支付，以支持各州和地方政府解决阿片类药物相关问题。公司已在截至2024年12月31日的年度报告（表格10-K）中计提了潜在和解金的估计金额。公司还将继续发挥其在解决紧迫的公共卫生挑战（如与阿片类药物相关的问题）方面的长期作用。例如，公司生产了一种可挽救生命的过量用药逆转药物纳洛酮（naloxone）的通用注射剂，以及一种用于治疗阿片类药物成瘾的布普品/纳洛酮（buprenorphine/naloxone）通用产品。公司还在开发一种非阿片类止痛药美洛昔康（meloxicam）的新型给药方式。此次和解使公司能够进一步专注于其使命，即为全球人民在生命的每个阶段赋能，使其过上更健康的生活，通过扩大的创新产品组合推进其解决未满足患者需求的工作，并继续以其多样化的药品组合为全球约10亿患者提供服务。相关阅读相比Teva和艾伯韦（原艾尔建/阿特维斯），晖致面临的诉讼并不算多，Teva和艾伯韦的诉讼高达3000多条，为了解决这些诉讼，Teva支付了42.5亿美元的和解费，而艾尔建也支付了23.7亿美元。药事纵横投稿须知：稿费已上调，欢迎投稿

PITTSBURGH, April 7, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) (the "Company") today announced it has reached a nationwide settlement framework to resolve opioid-related claims by states, local governments, and Tribes against the Company and certain of its subsidiaries. While the Company's presence in the U.S. opioids market is very small, the Company has agreed to this settlement to provide closure on these matters. This settlement is in no way an admission of wrongdoing or liability. Under the agreed upon framework, depending on the level of participation in the settlement, the Company would pay up to a maximum of $335 million, consisting of annual payments over a nine-year period of between approximately $27.5 and $40 million each, to help support state and local efforts to address opioid-related issues. The Company had already accrued an estimate in respect of a potential settlement, which is reflected in the Company's annual report on Form 10-K for the year ended December 31, 2024. The Company will also continue its longstanding role of working to identify solutions to address pressing public health challenges like those relating to opioids. For example, the Company manufactures a generic injectable version of the life-saving overdose reversal drug, naloxone, as well as a generic buprenorphine/naloxone product used for the treatment of opioid addiction. The Company is also developing a novel delivery for meloxicam, a non-opioid pain medication. The settlement enables the Company to further focus on its mission of empowering people worldwide to live healthier at every stage of life, advance its efforts to address unmet patient needs through an expanded innovative portfolio and continue to serve approximately 1 billion patients annually with its diverse portfolio of medicines. About Viatris Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter). Forward-Looking Statements This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements regarding the Company's nationwide settlement framework to resolve opioid-related claims by states, local governments, and Tribes against the Company and certain of its subsidiaries; under the agreed upon framework, depending on the level of participation in the settlement, the Company would pay up to a maximum of $335 million, consisting of annual payments over a nine-year period of between approximately $27.5 and $40 million each, to help support state and local efforts to address opioid-related issues; that the Company will also continue its longstanding role of working to identify solutions to address pressing public health challenges like those relating to opioids; the Company is also developing a novel delivery for meloxicam, a non-opioid pain medication; and that the settlement enables the Company to further focus on its mission of empowering people worldwide to live healthier at every stage of life, advance its efforts to address unmet patient needs through an expanded innovative portfolio and continue to serve approximately 1 billion patients annually with its diverse portfolio of medicines. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the inability or unwillingness on the part of any of the parties to agree to a final settlement; any legal or regulatory challenges to the settlement; the level of participation by litigants or claimants in the settlement framework; any failure by third parties to comply with their contractual obligations; actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; Viatris' failure to achieve expected or targeted future financial and operating performance and results; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, tariffs and trade policies, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. SOURCE Viatris Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED